Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333363 | 1.00 | LRRK2 (0.38) | LRRK2MAPK1GRM5PDE1APDE1B | |
| SCHEMBL1333361 | 1.00 | LRRK2 (0.38) | LRRK2MAPK1GRM5PDE1APDE1B | |
| SCHEMBL1334448 | 0.86 | GRM5 (0.44) | MAPK1GRM5CDK9CDK7MAPK8 | |
| SCHEMBL1334449 | 0.86 | GRM5 (0.44) | MAPK1GRM5CDK9CDK7MAPK8 | |
| SCHEMBL1334410 | 0.83 | MAPK8 (0.39) | LRRK2MAPK1GRM5PDE1BMAPK8 | |
| SCHEMBL1334397 | 0.83 | MAPK8 (0.39) | LRRK2MAPK1GRM5PDE1BMAPK8 | |
| SCHEMBL1334401 | 0.83 | MAPK8 (0.39) | LRRK2MAPK1GRM5PDE1BMAPK8 | |
| SCHEMBL14231044 | 0.78 | GRM5 (0.42) | MAPK1GRM5CDK9MAPK8MAPK9 | |
| SCHEMBL1333991 | 0.78 | GRM5 (0.39) | MAPK1GRM5MAPK8MAPK9 | |
| SCHEMBL1333993 | 0.78 | GRM5 (0.39) | MAPK1GRM5MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | LRRK2 3055/4885MAPK1 4410/4885GRM5 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.